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Abstract 
Epidemiologic studies have associated obesity with increased risk of the aggressive basal-like breast cancer (BBC) sub-
type. Hepatocyte growth factor (HGF) signaling through its receptor, cMET, is elevated in obesity and is a pro-tumori-
genic pathway strongly associated with BBC. We previously reported that high fat diet (HFD) elevated HGF, cMET, and 
phospho-cMET in normal mammary gland, with accelerated tumor development, compared to low fat diet (LFD)-fed 
lean controls in a murine model of BBC. We also showed that weight loss resulted in a significant reversal of HFD-
induced effects on latency and elevation of HGF/cMET signaling in normal mammary and cMET in normal mammary 
and tumors. Here, we sought to inhibit BBC tumor progression in LFD- and HFD-fed C3(1)-Tag BBC mice using a small 
molecule cMET inhibitor, and began crizotinib treatment (50 mg/kg body weight by oral gavage) upon identification 
of the first palpable tumor. We next investigated if administering crizotinib in a window prior to tumor development 
would inhibit or delay BBC tumorigenesis. Treatment: Crizotinib significantly reduced mean tumor burden by 27.96 
and 37.29 %, and mean tumor vascularity by 35.04 and 33.52 %, in our LFD- and HFD-fed C3(1)-Tag BBC mice, respec-
tively. Prevention: Crizotinib significantly accelerated primary tumor progression in both diet groups but had no effect 
on total tumor progression or total tumor burden. In sum, cMET inhibition by crizotinib limited tumor development 
and microvascular density in basal-like tumor-bearing mice but did not appear to be an effective preventive agent for 
BBC.
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Background
Basal-like breast cancer (BBC) accounts for 15–20  % of 
total breast cancers, with a higher prevalence in young 
and minority women such as African Americans and His-
panics (Carey et  al. 2006; Boyle 2012). BBC is typically 
estrogen receptor (ER), progesterone receptor (PR) and 
human epidermal growth factor receptor-2 (HER2) nega-
tive (so called “triple-negative”) and is highly aggressive, 
exhibiting an early pattern of metastasis and poor overall 
prognosis. Thus, BBC presents a formidable challenge, as 
it lacks the molecular targets for current targeted drug 
treatments. High body mass index (BMI) is associated 
with poorer prognosis in breast cancer patients, includ-
ing increased risk of  lymph node metastasis, vascular 
invasion,  disease recurrence,  and mortality (Dawood 
et al. 2008; Calle et al. 2003; Biglia et al. 2013). Epidemio-
logic studies indicate that obesity is strongly associated 
with the BBC subtype in both pre- and post-menopausal 
women (Biglia et al. 2013; Boyle 2012). In obesity, rapid 
expansion in mammary adipose tissue leads to altera-
tions in the stroma that mediate normal and tumor 
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microenvironment dysfunction yet are poorly under-
stood in breast cancer risk and progression (Iyengar et al. 
2015; Ford et  al. 2013; Johnson et  al. 2012; Sundaram 
et  al. 2013b). Given that obesity has increasing preva-
lence and is one of few modifiable risk factors for breast 
cancer, it is important to better elucidate the mechanisms 
for this obesity-associated cancer.
We have shown that BBC is characterized by unique 
epithelial-stromal interactions, which likely play a role in 
BBC etiology (Camp et al. 2011; Casbas-Hernandez et al. 
2013; Brauer et al. 2013; Stewart et al. 2012). An elevated 
level of hepatocyte growth factor (HGF), a pleiotropic 
growth factor that signals through the receptor tyrosine 
kinase cMET, is characteristic of BBC. Elevation of HGF 
is also seen in obese patients (Bell et  al. 2006). HGF/
cMET signaling initiates an invasive growth program 
that promotes cell migration, invasion, proliferation, and 
angiogenesis (Mizuno and Nakamura 2013). Endothelial 
cell upregulation of cMET has been attributed to inher-
ent or acquired resistance to antiangiogenic therapies 
targeting vascular endothelial growth factor (VEGF) in 
patients (Shojaei et  al. 2010; Ding et  al. 2003). Marking 
the first work in preclinical models paralleling human 
epidemiologic BBC findings, we used C3(1)-TAg mice, 
a unique genetically engineered mouse model (GEMM) 
of spontaneous BBC, to demonstrate  that high fat diet 
(HFD)-induced obesity accelerated onset of tumor devel-
opment and increased tumor aggressiveness as compared 
to low fat diet (LFD)-fed lean controls (Sundaram et  al. 
2013a). HFD also increased mammary gland HGF con-
centration and enhanced expression and activation of 
cMET. Using primary murine fibroblasts isolated from 
mammary glands or tumors, we further reported that 
obesity increased HGF production by mammary gland 
normal- and cancer-associated fibroblasts (NAF and 
CAF) (Sundaram et  al. 2013a). Through signaling inhi-
bition via an HGF blocking antibody, we showed that 
obese CAF-induced epithelial cell migration occurred 
in an HGF-dependent mechanism. Furthermore, using 
the intervention strategy of weight loss prior to tumor 
latency, we reported that weight loss blunted effects of 
HFD-induced obesity on multiple tumor parameters 
compared to mice maintained on HFD. Importantly, 
HFD-induced elevation of HGF/cMET signaling in nor-
mal mammary gland and cMET in tumors was signifi-
cantly reversed with weight loss in C3(1)-Tag mice, with a 
concomitant and complete reversal of HFD-driven tumor 
progression (Sundaram et al. 2014b).
Given the precedent for the role of HGF signaling 
in invasive breast cancer (Gastaldi et  al. 2010), a better 
understanding of HGF’s role in BBC tumorigenesis was 
necessary. We hypothesized that inhibition of cMET 
signaling through crizotinib therapy (PF-02341066) 
would reduce HFD-induced BBC. We first sought to 
inhibit tumor progression in existing tumors and began 
crizotinib treatment upon identification of the first pal-
pable tumor. Crizotinib significantly reduced total tumor 
burden in both LFD- and HFD-fed C3(1)-Tag mice, with 
a corresponding reduction in microvascular density. 
We next investigated whether we could inhibit or delay 
tumorigenesis by treating C3(1)-Tag mice with crizotinib 
prior to tumor development. Crizotinib treatment para-
doxically increased progression of the initially detected 
tumor in both diet groups. However, at sacrifice there 
were no differences between diet or treatment groups in 
total preneoplastic lesions, total tumor progression or 
tumor burden. In summary, cMET inhibition disrupted 
tumor vascularization and limited subsequent BBC 
tumor development in tumor-bearing mice. Our results 
suggest that reduction of microvascular density through 
cMET inhibition may be a viable therapeutic target in the 
treatment of BBC.
Results
Basal‑like tumor latency was accelerated by HFD
Adult female C3(1)-Tag mice were randomly assigned to 
diet groups at 10 weeks of age (Additional file 1: Figure 
S1A, Model of Treatment study design) and body weight 
and body composition were monitored. Tumor latency 
and progression were tracked by palpation and calipers. 
Body weight was not significantly altered by diet or vehi-
cle or drug treatment group for the study duration (Addi-
tional file 1: Figure S1B). Consistent with our previously 
reported results (Sundaram et al. 2013a), C3(1)-Tag mice 
fed HFD exhibited significantly decreased tumor latency 
compared with mice fed LFD (LFD median 17.3 weeks,; 
HFD median 15.5  weeks; P  <  0.0001, Fig.  1a). Using a 
Chi square test with a degree of freedom of 1, LFD vs 
HFD equaled 15.72. Adiposity as measured by MRI 
was increased with HFD but did not reach significance 
(Fig. 1b). Oral gavage of vehicle or drug slightly reduced 
adiposity among all groups, irrespective of diet or treat-
ment (Fig.  1b). Gonadal fat pad mass was significantly 
greater in mice fed HFD compared to mice fed LFD 
(P = 0.0173, Fig. 1c).
Crizotinib treatment inhibited secondary tumor 
development
Crizotinib treatment significantly reduced total tumor 
burden, by 27.96 and 37.29 % in LFD- and HFD-fed C3(1)-
Tag mice, respectively, compared to mice treated with 
vehicle (P = 0.0085, Fig. 1d). A minor diet effect on tumor 
burden was detected; HFD-fed animals in both vehicle- 
and crizotinib-treated groups showed reduced tumor bur-
den at sacrifice compared to LFD-fed mice (P =  0.0491, 
Fig.  1d). Tumor progression of all palpable tumors was 
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monitored using calipers throughout the 3-week meas-
urement period between latency and sacrifice. No dif-
ferences by diet or treatment group in primary tumor 
progression were detected (Additional file 1: Figure S1C).
Crizotinib disrupted tumor vascularization
CD31, a marker of angiogenic and lymphangiogenic 
microvessel density (MVD) (Choi et al. 2005), was meas-
ured by IHC (Fig. 2a–e). Crizotinib administration signif-
icantly reduced mean tumor MVD by 35.04 and 33.52 % 
in LFD and HFD groups, respectively (P = 0.014, Fig. 2f ). 
There were no diet effects on CD31 positivity. Total 
cMET staining did not differ by diet or treatment group 
(Additional file  2: Figure S2A), while phosphorylated 
(active) cMET was significantly higher in mice fed HFD 
(P = 0.014, Additional file 2: Figure S2B).
Crizotinib prophylactic treatment did not affect body 
weight or adiposity
As crizotinib treatment reduced tumor burden in tumor-
bearing mice, we next investigated whether we could inhibit 
or delay tumorigenesis by treating with crizotinib prior 
to tumor development. C3(1)-Tag tumors progress along 
the following timeline: atypical hyperplasia (AH) of the 
mammary ductal epithelium at 8 weeks of age, mammary 
intraepithelial neoplasia (resembling human carcinoma 
in situ [CIS]) at 12 weeks of age, and invasive carcinomas 
at 16  weeks of age with 100  % penetrance (Green et  al. 
2000). Thus, in the prevention arm of the study, mice were 
started on diet 2 weeks earlier than in the treatment study 
above to ensure crizotinib administration occurred within 
the primary window of AH/CIS precursor lesions. Start-
ing at 8 weeks of age, mice were randomly assigned to LFD 
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Fig. 1 HFD accelerated tumor latency but reduced tumor burden, while crizotinib treatment blunted tumor burden regardless of diet. a Tumor 
latency was reported as age at detection of the first palpable tumor (LFD median 17.3 weeks, N = 24; HFD median 15.5 weeks, N = 22; P < 0.0001). 
b Body composition was measured at diet start, tumor latency (week 0 of crizotinib), 1.5 weeks on crizotinib treatment, and 3 weeks on crizotinib 
treatment (at sacrifice). c Gonadal fat pad mass was weighed at sacrifice (LFD vs. HFD N = 11–13 per group *P = 0.017). d Total number of visible 
tumors was assessed at sacrifice (LFD vs HFD *P = 0.0491; Vehicle (a) versus crizotinib (b) P = 0.0085)
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or HFD, with crizotinib treatment beginning at 9 weeks of 
age and continuing until 12 weeks of age (Additional file 3: 
Figure S3A). Mice fed HFD diet gained significantly more 
weight than the LFD mice, with greater body weights from 
9 to 16 weeks of age (P  < 0.05, Additional file 3: Figure S3B). 
Body composition differed significantly between LFD- and 
HFD-fed mice beginning at 1 week on diet (9 weeks of age) 
and remained significant until sacrifice (P < 0.0001 for all 
data points, Fig.  3a). Crizotinib- and vehicle-treated mice 
fed HFD had significantly greater gonadal fat pad mass 
when compared to LFD-fed mice (P  <  0.0001, Fig.  3b). 
No difference was detected in body weight or adiposity 
between the crizotinib and vehicle treated mice (Fig. 3a, b).
Crizotinib prophylactic treatment increased tumor 
progression but did not significantly alter tumor burden or 
precursor lesions
Upon initiation of crizotinib or vehicle administration mice 
were palpated twice weekly for detection of tumor onset. 
Median tumor latency did not vary significantly between 
diet or treatment groups (LFD vehicle-treated median 
15.0  weeks; LFD crizotinib-treated median 16.1  weeks; 
HFD vehicle median 16.0  weeks; HFD crizotinib median 
16.2  weeks, Fig.  3c). Progression of the primary, initially 
detected tumor was significantly increased with crizotinib 
treatment in both diet groups (P = 0.04, Additional file 3: 
Figure S3C). However, when all tumors were considered 
there were no differences between diet or treatment groups 
in total tumor progression (Additional file 3: Figure S3D) or 
tumor burden (Fig. 3d) at sacrifice. Non-tumor mammary 
tissue was analyzed for AH and CIS premalignant lesions in 
of HFD-fed vehicle- or crizotinib-treated mice. There were 
no significant diet- or crizotinib-mediated effects on precur-
sor lesion formation detected (Additional file 3: Figure S3E).
Discussion
The HGF/cMET pathway is regulated by body weight 
and is relevant to BBC. HGF is the only known ligand for 
cMET, and the HGF/cMET signaling pathway has long 
been studied in normal development, ductal morpho-
genesis (Garner et al. 2011), invasive breast cancer (Tuck 
et al. 1996; Yamashita et al. 1994; Elliott et al. 2002; Wang 
et al. 1994; Jin et al. 1997; Beviglia et al. 1997), and inva-
sive biology of several other cancers due to its angiogenic, 
mitogenic, and morphogenic effects (Stella et al. 2005; Sam 
et al. 2007). Notably, single nucleotide polymorphisms in 
the MET gene may be associated with metastatic breast 
cancer (Liu 2015). In patients, we demonstrated that 
86  % of BBC expressed an HGF/cMET activation signa-
ture through gene expression (Casbas-Hernandez et  al. 
2013). Furthermore, a recent comprehensive meta-anal-
ysis including over 6000 cases showed that cMET over-
expression is significantly associated with poor survival 
in breast cancer patients, particularly among patients 
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Fig. 2 Crizotinib impaired tumor vascularization. a–e Representative photomicrographs (40×) of CD31 staining in negative control and indicated 
LFD, HFD, vehicle (veh) and crizotinib (criz) treated groups. b CD31 was quantified on 5–6 randomly selected regions of n = 2 sections each from 
each mouse. N = 9–10 mice (a vs b, Veh vs Criz, P = 0.0138)
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with triple-negative breast cancer (Yan et al. 2015). Obe-
sity mediates, and can exacerbate, both normal and tumor 
microenvironment dysfunction (Johnson et al. 2012; Sund-
aram et al. 2013b). HGF is an excellent candidate media-
tor of obesity-induced effects on cancer, as serum HGF is 
elevated in obese individuals and reduced with weight loss 
(Hiratsuka et al. 2005; Bell et al. 2006; Swierczynski et al. 
2005). Moreover, adipose-derived HGF has been detected 
in normal and malignant breast tissue (Tuck et al. 1996).
We have previously demonstrated that HFD expo-
sure during adulthood increased cMET expression and 
activation in normal mammary and tumors (Sundaram 
et  al. 2013a). Diet-induced upregulation of cMET in 
tumors was also evident in mice fed HFD from weaning 
and could be reversed by weight loss (Sundaram et  al. 
2014b). Our previous work further revealed that HFD-
induced weight gain resulted in increased mammary 
gland HGF that was reversed with weight loss (Sundaram 
et al. 2014b). Reduction in HGF due to weight loss cor-
related with diminished tumor progression or decelera-
tion of tumor latency, depending on whether the diet was 
initiated at weaning or adult onset, respectively. Alto-
gether, our previously published studies on HGF/cMET 
implicated HGF/cMET signaling as a mediator of obe-
sity-driven BBC tumor aggression. Therefore, this study 
aimed to specifically inhibit cMET signaling as a poten-
tial BBC treatment or prevention strategy, hypothesizing 
that disruption of HGF/cMET signaling would mimic the 
effects of weight loss on BBC tumorigenesis.
C3(1)Tag mice are a GEMM that develop BBC in 100 % 
of female mice (Green et al. 2000). Initial characterization 
of the C3(1)-Tag model reported grossly palpable tumors 
at ~16 weeks of age; in our hands, median tumor latency 
occurs between 15 and 19  weeks, dependent on diet 
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Fig. 3 Preventive administration of crizotinib prior to tumor onset did not alter tumor parameters. Diet was started at 8 weeks of age (baseline). a 
Body composition was measured by MRI (LFD vs. HFD *P < 0.0001). b Gonadal fat pad mass was determined at sacrifice (LFD vs. HFD *P < 0.0001). 
c Upon initiation of crizotinib treatment (50 mg/kg by oral gavage) at 9 weeks of age, mice were palpated twice weekly for tumor onset. Median 
tumor latency did not differ with diet or treatment (LFD veh-treated median 15.0 weeks, N = 22; LFD criz-treated median 16.1 weeks, N = 21; HFD 
veh-treated median 16.0 weeks; HFD criz-treated median 16.2 weeks). d Total tumor burden was assessed at sacrifice
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composition and age at diet start (Sundaram et al. 2013b, 
2014a, b). Several groups have reported “windows of sus-
ceptibility” during which HFD and/or obesity may play a 
disproportionately greater role in promoting breast cancer 
onset (Biro and Deardorff 2013; Sundaram et  al. 2013b). 
As shown here, in the crizotinib treatment arm of our 
study, initiating diets at 10 weeks of age resulted in detec-
tion of tumor latency two weeks earlier in mice that were 
fed HFD compared to mice fed LFD, consistent with our 
previous C(3)1-Tag studies in which identical diets were 
initiated at the same age (Sundaram et al. 2013a). However, 
in the crizotinib prevention arm of our study, in which 
HFD was initiated at 8 weeks of age, we did not see this 
diet effect of accelerated latency—these results parallel our 
second previously published study, in which female C3(1)-
Tag mice were weaned onto LFD or HFD and no differ-
ence in latency was observed (Sundaram et  al. 2014b). 
Interestingly, pubertal exposure to HFD has been linked to 
stunted mammary duct elongation and reduced mammary 
epithelial cell proliferation in murine models (Olson et al. 
2010), a finding that was not seen in mice started on diet at 
10 weeks of age or older. Collectively, our results here and 
in our previous studies support the concept that exposures 
extrinsic to the cancer cell (i.e., diet-induced alterations in 
the mammary microenvironment) can impact tumorigen-
esis, while age at diet start may be an important variable 
contributing to diet effects on tumor latency.
Herein, we showed that crizotinib treatment after BBC 
latency inhibited subsequent tumor formation such that 
total tumor burden was reduced at sacrifice, regardless 
of diet. The degree of tumor inhibition was paralleled by 
a similar degree of suppression of MVD, also irrespec-
tive of diet. Reduction in MVD in our crizotinib-treated 
tumor-bearing C3(1)-Tag mice could explain the sig-
nificant reduction of tumor burden compared to vehi-
cle-treated controls. In tumors, an “angiogenic switch” 
occurs, in which an increase in MVD in and near the 
tumor allows for tumor survival and metastasis (Lin and 
Pollard 2007). Increases in HGF in the tumor microen-
vironment contribute to this angiogenic switch (Wagat-
suma et  al. 1998; Abounader and Laterra 2005), while 
cMET signaling by the cancer cells facilitates invasion 
and migration away from the hypoxic interior of the 
tumor, entry into the new and leaky vessels, and metas-
tasis to distant locations (Gastaldi et  al. 2010). Indeed, 
obesity-promoted HGF production by fibroblasts, adi-
pocytes, macrophages, and endothelial cells (Sundaram 
et al. 2013a, 2014b; Casbas-Hernandez et al. 2011, 2013; 
Mizuno and Nakamura 2013) may be a unique mecha-
nism to increase blood vessel density and alleviate the 
hypoxia of obese adipose tissue. The fact that no changes 
were detected in latency in the prevention arm of our 
study suggests that early changes in the HGF/cMET axis 
(i.e., prior to invasive carcinoma) may not be as easily tar-
geted, or are not causative in BBC tumorigenesis.
Initial mechanism-of-action studies for crizotinib showed 
that dose-dependent inhibition of cMET in gastric carci-
noma, glioblastoma, and prostate carcinoma resulted in 
reduction of MVD as measured by CD31 (Zou et al. 2007). 
Inhibition of cMET as an effective anti-angiogenic agent 
has also been shown in xenograft models of aggressive can-
cers such as lung (Puri et al. 2007) and pancreatic cancers 
(You et al. 2011). Moreover, the use of other cMET inhibi-
tors in triple-negative breast cancer models such as ours 
has yielded promising results in preclinical studies (Sameni 
et al. 2015). However, to date clinical trials using the cMET 
inhibitors tivantinib or onartuzamab in isolation or in com-
bination with chemotherapy have demonstrated little ther-
apeutic benefit in metastatic breast cancer (Tolaney et  al. 
2015; Dieras et al. 2015; Sharma and Adjei 2011). Clinical 
trials investigating crizotinib alone [ClinicalTrials.gov:NCT 
02101385 (Schneider 2016)] or in combination with anti-
VEGF therapy [ClinicalTrials.gov:NCT 02074878 (Baylor 
Breast Care Center 2015)] for the treatment of advanced 
triple negative breast cancer are currently underway. Breast 
cancer ranks as the fifth cause of death from cancer overall 
and is now the second cause of cancer death following lung 
cancer (Brewster et al. 2014; WHO 2014). With the grow-
ing global prevalence of obesity and the notable racial and 
ethnic disparities in BBC outcomes (Brewster et al. 2014), 
it is imperative that approaches are identified to effectively 
address the increased risk of breast cancer onset and pro-
gression to malignancy for an increasingly overweight and 
obese US population.
Methods
Antibodies and drugs
Crizotinib (PF-2341066 [(R)-3-[1-(2,6-dichloro-3-fluoro-
phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-
pyridin-2-ylamine) was purchased from Selleck Chemical 
(Catalog No. S1068). Primary antibodies include: Rabbit 
anti-mouse CD31 (Abcam #ab28364, Lot GR212364-
5; 1:400); Rabbit anti-mouse phospho-cMET (Abcam 
#ab5662, Lot GR159296-1; 1:4000); Goat anti-mouse 
cMET (R&D Systems #AF527, Lot CTB0310091; 1:1000) 
diluted in Renoir Red Diluent (BM #PD904H). Additional 
reagents included biotin-conjugated Goat anti-rabbit IgG 
(Jackson #111-065-144, Lot 110335; 1:500); Donkey anti-
goat IgG (Jackson #705-065-147, Lot 110544; 1:1000). 
ABC Elite (Vector #PK-6100, 1:50) and 3,3′ Diaminoben-
zidine (DAB) (Thermo Scientific #TA-125-QHDX).
Animals and diet
Animal studies were performed with approval and in 
accordance with the guidelines of the Institutional Ani-
mal Care and Use Committee at the University of North 
Page 7 of 10Cozzo et al. SpringerPlus  (2016) 5:348 
Carolina at Chapel Hill. Animals were cared for accord-
ing to the recommendations of the Panel on Euthanasia 
of the American Veterinary Medical Association. The vet-
erinary care provided at UNC is in compliance with the 
Public Health Service Policy on Humane Care and Use of 
Laboratory Animals and meets the National Institutes of 
Health standards as set forth in the Guide for the Care and 
Use of Laboratory Animals (DHHS Publication No. (NIH) 
85-23 Revised 1985). The animal facility is Association for 
Assessment and Accreditation of Laboratory Animal Care 
(AAALAC) approved and is responsible for the health and 
husbandry of animals. UNC also accepts as mandatory the 
PHS Policy on Humane Care and Use of Laboratory Ani-
mals be Awardee Institutions and NIH Principles for the 
Utilization and Care of Vertebrate Animals Used in Testing, 
Research, and Training. Animal studies comply with the 
ARRIVE guidelines. Mice were housed in a climate con-
trolled Department of Laboratory Animal Medicine facility 
with a 12 h light:dark cycle and ad libitium access to food 
and water or special diets as defined below. Female C3(1)-
Tag mice were obtained in collaboration with the UNC 
Lineberger Comprehensive Cancer Center (LCCC) Mouse 
Phase I Unit (MP1U). C3(1)-Tag mice (Green et al. 2000), 
a model of BBC, were generated by crossing heterozygous 
male mice with FVB/N non-transgenic female mice.
For the tumor treatment study, N  =  46 female C3(1)-
Tag mice were bred and maintained on chow diet (Harlan 
2918) until nulliparous female were randomly assigned to 
LFD (N = 24) and HFD (N = 22) at 10 weeks of age. Diets 
obtained from Research Diets Inc. (New Brunswick, NJ, 
USA) were matched for protein, vitamins, and minerals, 
and provided 10 % kcal (“LFD”; # D11012202); and 60 % kcal 
(“HFD”; # D11012204) derived from fat. Diets were sucrose-
free, and soy-free. Additional details of diet components 
are provided in Sundaram et  al. (Sundaram et  al. 2013a). 
Model of treatment study design is supplied in Additional 
file 1: Figure S1A). For the prevention study, during breed-
ing and after weaning mice were put on Prolab Isopro RMH 
3000 from LabDiet (St. Louis, MO, USA). At 8 weeks of age, 
nulliparous female C3(1)-Tag mice were randomly assigned 
to LFD (N = 43) and HFD (N = 45) diet groups (Model of 
treatment study design, Additional file 3: Figure S3A).
Tumor latency, number, and progression
Mice were monitored for tumor development by palpat-
ing twice weekly. Tumor latency defined as age in weeks 
at detection of first tumor. Tumor volumes were meas-
ured twice weekly over 3 weeks using calipers to measure 
the width (short diameter) and length (long diameter) in 
millimeters for each tumor. Tumor volumes were calcu-
lated using the formula: length ×  width2 ×  0.5. Tumor 
progression is reported as percent change in volume 
from latency to sacrifice 3 weeks later. Primary tumor 
progression refers to the first tumor identified; total 
tumor progression includes all tumors palpated. The total 
number of visible tumors per mouse was counted at sac-
rifice for total tumor burden.
Crizotinib treatment
Crizotinib dosage was 50 mg crizotinib/kg of body weight 
(Zou et al. 2007). In the treatment study, crizotinib admin-
istration by oral gavage began at identification of the first 
palpable tumor and persisted for 3  weeks until sacrifice 
(5  days on drug, 2  days rest) (Additional file  1: Figure 
S1A). Briefly, drug was prepared by dissolving 20  mg of 
crizotinib powder in 200 µL 1 N hydrochloric acid (HCl), 
then brought to a total volume of 1 mL with vehicle (0.5 % 
glucose in phosphate-buffered saline) to yield a 2× crizo-
tinib solution. Immediately prior to gavage administra-
tion, the 2x solution was diluted with an equal volume 
of vehicle to yield a 1x solution. In the prevention study, 
drug was prepared as a 1x solution by dissolving 10 mg of 
crizotinib powder in 200 µL 1 N hydrochloric acid (HCl), 
then brought to a total volume of 1 mL with vehicle; cri-
zotinib treatment began for all mice at 9 weeks of age and 
continued for 3 weeks (5 days on drug, 2 days rest).
Body weight and composition
Body weight was measured at start of diet and weekly 
until sacrifice. Body composition including lean mass, fat 
mass, free water content and total water content of non-
anesthetized mice was measured using EchoMRI-100 
quantitative magnetic resonance whole body composition 
analyzer (Echo Medical Systems, Houston, TX). Fat mass 
is presented as percent fat mass over total body weight 
(Sundaram et al. 2013a, 2014b). There were no significant 
changes in absolute lean mass in grams (data not shown).
Tissue and blood collection
Three weeks after detection of the first palpable tumor, 
mice were fasted for 6  h and anesthetized by an intra-
peritoneal (i.p.) injection of avertin (tribromoethanol/
amylene hydrate, 1.25 %) (Sigma Aldrich, St. Louis, MO). 
Blood was collected via cardiac puncture using an EDTA-
coated syringe into 5 µL of 250 mM EDTA. Plasma was 
separated from other blood components by centrifuga-
tion at 10,000×g for 2  min at 4  °C. Mammary tumors, 
unaffected inguinal mammary gland, liver, spleen, and 
lungs were flash frozen in liquid nitrogen or were placed 
into a cassette and formalin-fixed for immunohistochem-
istry (IHC) and H&E analysis. All frozen samples were 
stored at −80 °C until analyzed.
Immunohistochemistry
Briefly, formalin-fixed and paraffin-embedded tissues were 
sectioned at 5 microns and mounted for histological staining 
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(Sundaram et al. 2013a). Tissues were baked, deparaffinized, 
and hydrated. Following heat-induced epitope retrieval 
(Rodent Decloaker BM#RD913L), slides were treated with 
3  % hydrogen peroxide in de-ionized water. Tissues were 
treated with Avidin/Biotin Block (Vector #SP-2001) and 
exposed to primary antibodies (anti-CC3, anti-Ki67 anti-
CD31; anti-phospho-cMET; anti-cMET) diluted in Renoir 
Red Diluent at 4  °C overnight. Following incubation with 
biotin-conjugated secondary antibodies [Goat anti-rabbit 
IgG; Donkey anti-goat IgG] tissue sections were treated 
with ABC Elite and DAB. Digital immunohistochemistry 
quantification was performed following the protocol previ-
ously described in Sundaram et  al. (2013a). Stained slides 
were scanned into the Aperio Scanscope CS system (Aperio 
Technologies, Vista, CA, USA) at a magnification of 40× 
and were quantified using the Aperio Imagescope software. 
Scanned slides were analyzed using algorithms as described 
previously (Sundaram et al. 2014a). N  =  5–6 random areas 
from sections (n  =   2 sections per mouse) were quantified 
and averaged per tumor per animal (n  =  9–10 mice per diet 
or exposure group). Images shown are representative.
Statistical analysis
Data are expressed as mean ± standard error of the mean 
(SEM). All means were compared by 2 way analysis of 
variance (ANOVA) with Tukey’s post hoc test for statisti-
cal differences using GraphPad Prism 5 software (Graph-
Pad Software, Inc. La Jolla, CA). Kaplan–Meier analyses 
were conducted using GraphPad Prism 5 software to esti-
mate tumor latency. Log rank and Chi square tests were 
used to investigate differences among groups. P values 
<0.05 were considered statistically significant.
Additional files
Additional file 1: Figure S1. A) Model of Treatment Study design. 
At 10 weeks of age female mice were randomized to LFD or HFD and 
palpation began for identification of tumor onset. Vehicle or crizotinib 
treatment by oral gavage began at detection of first palpable tumor 
and lasted for 3 weeks, 5 days on and 2 days off. Mice were sacrificed 
at 3 weeks past tumor onset. Metabolic and other parameters were 
measured as indicated. B) Body weights did not differ by diet or treatment 
group. No significant differences were observed in C) primary or D) total 
tumor progression.
Additional file 2: Figure S2. A) Total MET staining did not differ by diet 
or treatment group. B) Phosphorylated (active) MET was significantly 
higher in mice fed HFD (2-way ANOVA *P = 0.0141).
Additional file 3: Figure S3. A) Model of Prevention Study design. At 
8 weeks of age female mice were randomized to LFD or HFD. At 9 weeks 
of age vehicle or crizotinib treatment by oral gavage began and lasted 
for 3 weeks, 5 days on and 2 days off. Palpation began for identification of 
tumor onset also began at 9 weeks of age. Mice were sacrificed at 3 weeks 
past tumor onset. Metabolic and other parameters were measured as indi-
cated. B) Mice fed HFD diet gained significantly more weight than the LFD 
mice, with greater body weights from 9 to 16 weeks of age (LFD vs HFD 
*P  < 0.05). Progression of the primary tumor was significantly increased 
with crizotinib treatment in both diet groups (a vs b, P = 0.036), but had 
no effect on total tumor progression or total tumor burden.
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